• Opdivo and Yervoy Combo Seen to Outperform Sutent in Untreated Advanced Kidney Cancer, But More Data Needed
  • Brain Cancer Vaccine SurVaxM Receives FDA Orphan Drug Status
  • New Immuno-Oncology Therapy Against Advanced Solid Tumors to Enter Phase 1 Clinical Studies
  • Dozens of New Genes with Resistance to Cancer Immunotherapy Discovered
  • FDA Approves Opdivo for Two Metastatic Colorectal Cancers That Failed to Respond to Chemo
  • FDA Grants Breakthrough Therapy Status to Imfinzi for Unresectable NSCLC
  • Natural Killer Cells Are Important to Ceplene’s Ability to Keep Leukemia in Remission, Trial Shows
  • COX-2 Inhibitors May Improve Cancer Immunotherapy Response
  • Opdivo, Yervoy, and Keytruda May Induce Rare Adverse Reactions Affecting the Eye, FDA Says
  • NT-219 Re-sensitizes Cancer to Keytruda, Stopping Tumor Progression, Study Shows
  • Opdivo Extends Survival, Has Less Impact on Lives in Head and Neck Cancer Patients Than Standard Chemo, Study Shows
  • Celgene Working with BeiGene to Develop Its PD-1 Inhibitor, BGB-A317, to Treat Solid Tumors